693-97-0 Purity
95%
If you have any other questions or need other size, please get a quote.
Specification
Zhang, Peng, et al. Talanta, 2015, 134, 501-507.
This work demonstrates a pH-responsive drug delivery system based on doxorubicin-tethered fluorescent silica nanoparticles (DOX-Hyd@FSiNPs). The system couples DOX to FSiNPs via an acid-labile hydrazone linker, and the fluorescence properties allow the nanoparticles to be tracked inside cells. In vitro experiments showed that DOX-Hyd@FSiNPs can effectively release doxorubicin and successfully reduce the viability of HeLa cells in an acidic environment. Carboxyethylsilanetriol Na salt (25% in water) is the key raw material for carboxylic acid modification of FSiNPs.
· Synthesis of FSiNPs and carboxylic acid-modified FSiNPs
Fluorescein isothiocyanate (FITC) was conjugated with aminopropyltriethoxysilane (APTES) in n-hexanol to form FITC-APTES, followed by incorporation into a water-in-oil microemulsion system containing Triton X-100, cyclohexane, and tetraethyl orthosilicate (TEOS). Ammonium hydroxide initiated silica nanoparticle formation, which was isolated via acetone precipitation, centrifugation, and washing. The obtained FSiNPs were carboxylated using carboxyethylsilanetriol Na salt under acidic conditions, purified, and stored in aqueous suspension.
· Synthesis of doxorubicin-tethered FSiNPs
Carboxylic acid-functionalized FSiNPs were activated with EDC/NHS to enable hydrazine grafting via amide bonding. The hydrazine-modified nanoparticles (hydrazine@FSiNPs) were reacted with DOX in methanol, forming hydrazone-linked DOX-Hyd@FSiNPs. Unbound DOX was removed through repeated centrifugation and methanol washing. Drug-loading efficiency was quantified by UV-vis analysis of the supernatant, while the final conjugate was vacuum-dried for storage.
Chen, Zhen, et al.Biosensors and Bioelectronics, 2018, 122, 211-216.
A ZnO nanowire-coated three-dimensional (3D) scaffold chip device is proposed for efficient immunocapture and classical visible and colorimetric detection of exosomes with a minimum detectable concentration of 2.2 × 104 particles/μL. The ZnO chip device consists of a 3D polydimethylsiloxane (PDMS) scaffold skeleton covered with free-standing ZnO nanowire arrays (functionalized with carboxylic acids and CD63 monoclonal antibody).
Functionalization of ZnO chip device
Initially, the chip underwent plasma treatment for a duration of 3 minutes. The chip was exposed to a 5% carboxyethylsilanetriol sodium salt solution which incubated for 4 hours to achieve carboxyl coupling. After rinsing with water, a boric acid buffer (10 mM, pH 7.4) containing 25 mM 1-(3-(Dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (EDC) and 0.5 mg/mL streptavidin (SA) was pumped into the chip and left to react on ice for 4 hours. Any excess EDC and SA were then removed, and a 10 μg/mL biotin-labeled mouse anti-human CD63 monoclonal antibody was added to the chip for incubation for 1 hour. Finally, the chip was blocked using a solution of 5% BSA and 0.2% Tween-20, and then stored at 4 °C until needed.
Please kindly note that our products are for research use only.
Download